AR056832A1 - Procedimiento para tratar el crecimiento celular anormal - Google Patents

Procedimiento para tratar el crecimiento celular anormal

Info

Publication number
AR056832A1
AR056832A1 ARP060105369A ARP060105369A AR056832A1 AR 056832 A1 AR056832 A1 AR 056832A1 AR P060105369 A ARP060105369 A AR P060105369A AR P060105369 A ARP060105369 A AR P060105369A AR 056832 A1 AR056832 A1 AR 056832A1
Authority
AR
Argentina
Prior art keywords
procedure
treat abnormal
cellular growth
abnormal cellular
treat
Prior art date
Application number
ARP060105369A
Other languages
English (en)
Spanish (es)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR056832A1 publication Critical patent/AR056832A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
ARP060105369A 2005-12-05 2006-12-05 Procedimiento para tratar el crecimiento celular anormal AR056832A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74276605P 2005-12-05 2005-12-05
US86463706P 2006-11-07 2006-11-07

Publications (1)

Publication Number Publication Date
AR056832A1 true AR056832A1 (es) 2007-10-24

Family

ID=38123250

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060105369A AR056832A1 (es) 2005-12-05 2006-12-05 Procedimiento para tratar el crecimiento celular anormal

Country Status (20)

Country Link
US (1) US7825137B2 (enExample)
EP (1) EP1959955B1 (enExample)
JP (1) JP4619346B2 (enExample)
KR (1) KR101026676B1 (enExample)
AR (1) AR056832A1 (enExample)
AT (1) ATE488237T1 (enExample)
AU (1) AU2006323027B2 (enExample)
BR (1) BRPI0619424B1 (enExample)
CA (1) CA2632286C (enExample)
CY (1) CY1110931T1 (enExample)
DE (1) DE602006018354D1 (enExample)
DK (1) DK1959955T3 (enExample)
IL (1) IL191471A (enExample)
NZ (1) NZ568654A (enExample)
PL (1) PL1959955T3 (enExample)
PT (1) PT1959955E (enExample)
RU (1) RU2384331C2 (enExample)
SI (1) SI1959955T1 (enExample)
TW (1) TWI321050B (enExample)
WO (1) WO2007066187A2 (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101023064B (zh) 2004-08-26 2011-02-16 辉瑞大药厂 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物
DK1889836T3 (da) * 2005-08-24 2013-08-19 Eisai R&D Man Co Ltd Hidtil ukendt pyridinderivat og pyrimidinderivat
EP1963302B1 (en) * 2005-12-05 2013-02-27 Pfizer Products Inc. Polymorphs of a c-met/hgfr inhibitor
US20120208824A1 (en) 2006-01-20 2012-08-16 Cell Signaling Technology, Inc. ROS Kinase in Lung Cancer
US8168383B2 (en) 2006-04-14 2012-05-01 Cell Signaling Technology, Inc. Gene defects and mutant ALK kinase in human solid tumors
PL2450437T3 (pl) 2006-04-14 2017-12-29 Cell Signaling Technology Inc Defekty genu i zmutowana kinaza ALK w ludzkich guzach litych
CA2661333C (en) * 2006-08-23 2014-08-05 Eisai R&D Management Co., Ltd. Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
US7790885B2 (en) 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
JP2009132660A (ja) * 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
US20090227556A1 (en) * 2008-01-31 2009-09-10 Eisai R&D Management Co., Ltd. Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives
US20110206691A1 (en) * 2008-02-15 2011-08-25 Mosse Yael P Methods and Compositions for Treating Neuroblastoma
WO2009103061A2 (en) * 2008-02-15 2009-08-20 The Children's Hospital Of Philadelphia Methods and compositions for identifying, diagnosing, and treating neuroblastoma
JPWO2009104520A1 (ja) * 2008-02-18 2011-06-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 フェノキシピリジン誘導体の製造方法（２）
EP2143441A1 (en) * 2008-07-08 2010-01-13 Pierre Fabre Medicament Combination of a c-Met antagonist and an aminoheteroaryl compound for the treatment of cancer
CN101653607B (zh) * 2008-08-19 2013-02-13 鼎泓国际投资（香港）有限公司 含有肝细胞生长因子受体抑制剂和丝裂原细胞外激酶抑制剂的药物组合物及其用途
WO2010064300A1 (ja) * 2008-12-02 2010-06-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 食道癌治療用組成物
DE102009003954A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate
DE102009004061A1 (de) 2009-01-08 2010-07-15 Merck Patent Gmbh Pyridazinonderivate
JP5675850B2 (ja) 2010-02-05 2015-02-25 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ ヘタリール−［１，８］ナフチリジン誘導体
US8378104B2 (en) * 2010-02-11 2013-02-19 OSI Pharmaceuticals, LLC 7-aminofuropyridine derivatives
WO2011138751A2 (en) 2010-05-04 2011-11-10 Pfizer Inc. Heterocyclic derivatives as alk inhibitors
EP2586443B1 (en) 2010-06-25 2016-03-16 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
KR20130131293A (ko) 2010-07-05 2013-12-03 메르크 파텐트 게엠베하 키나아제 - 유도된 질환의 치료에 유용한 바이피리딜 유도체
US20120101108A1 (en) 2010-08-06 2012-04-26 Cell Signaling Technology, Inc. Anaplastic Lymphoma Kinase In Kidney Cancer
US9145390B2 (en) 2011-03-03 2015-09-29 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
WO2012119006A2 (en) * 2011-03-03 2012-09-07 Concert Pharmaceuticals, Inc. Derivatives of pyrazole-substituted amino-heteroaryl compounds
US9051318B2 (en) 2011-03-09 2015-06-09 Merck Patent Gmbh Pyrido [2, 3-B] pyrazine compounds and their therapeutical uses such as for inhibiting ATP consuming proteins and treating diseases associated therewith
WO2013041038A1 (en) * 2011-09-21 2013-03-28 Teligene Ltd. Pyridine compounds as inhibitors of kinase
CA2863515C (en) 2012-01-31 2018-02-27 Daiichi Sankyo Company, Limited Pyridone derivatives
KR101692600B1 (ko) 2012-03-06 2017-01-03 화이자 인코포레이티드 증식성 질환 치료용 거대환형 유도체
WO2013148537A1 (en) * 2012-03-29 2013-10-03 Ning Xi Substituted spirobicyclic compounds and methods of use
US20150056193A1 (en) 2012-04-18 2015-02-26 Cell Signaling Technology, Inc. Egfr and ros1 kinase in cancer
CN103509008A (zh) * 2012-06-22 2014-01-15 康瑟特制药公司 吡唑取代的氨基-杂芳基化合物的衍生物
WO2014020467A2 (en) 2012-07-30 2014-02-06 Fresenius Kabi Oncology Ltd Process for the preparation of pyrazole substituted aminoheteroaryl compounds
WO2014046730A1 (en) 2012-09-24 2014-03-27 Ventana Medical Systems, Inc. Method of identifying treatment responsive non-small cell lung cancer using anaplastic lymphoma kinase (alk) as a marker
CA2890006C (en) * 2012-11-06 2021-11-23 Shanghai Fochon Pharmaceutical Co Ltd Alk kinase inhibitors
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
EA201201654A1 (ru) * 2012-12-28 2014-06-30 Ооо "Эн.Си.Фарм" Противоопухолевое средство (варианты)
WO2014115169A2 (en) * 2013-01-24 2014-07-31 Hetero Research Foundation Crizotinib solid dispersion
KR20150118159A (ko) 2013-02-22 2015-10-21 에프. 호프만-라 로슈 아게 암의 치료 방법 및 약물 내성의 예방 방법
WO2014140159A1 (en) * 2013-03-13 2014-09-18 Ratiopharm Gmbh Dosage form comprising crizotinib
CA2912219C (en) 2013-05-14 2021-11-16 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
JP6291179B2 (ja) * 2013-07-26 2018-03-14 関東化學株式会社 光学活性２級アルコールの製造方法
US20160214961A1 (en) * 2013-09-10 2016-07-28 Shilpa Medicare Limited Novel salts of crizotinib and their preparation
RU2550346C2 (ru) 2013-09-26 2015-05-10 Общество с ограниченной ответственностью "Отечественные Фармацевтические Технологии" ООО"ФармТех" Новые химические соединения (варианты) и их применение для лечения онкологических заболеваний
EP3066118B1 (en) 2013-11-06 2020-01-08 The U.S.A. as represented by the Secretary, Department of Health and Human Services Alk antibodies, conjugates, and chimeric antigen receptors, and their use
TWI723572B (zh) 2014-07-07 2021-04-01 日商第一三共股份有限公司 具有四氫吡喃基甲基之吡啶酮衍生物及其用途
JP2017530950A (ja) 2014-08-25 2017-10-19 ファイザー・インコーポレイテッド 癌を処置するためのｐｄ−１アンタゴニストおよびａｌｋ阻害剤の併用
EP4089076A1 (en) 2014-08-28 2022-11-16 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
KR102763349B1 (ko) 2015-02-25 2025-02-07 에자이 알앤드디 매니지먼트 가부시키가이샤 퀴놀린 유도체의 고미 억제 방법
AU2015384801B2 (en) 2015-03-04 2022-01-06 Eisai R&D Management Co., Ltd. Combination of a PD-1 antagonist and a VEGFR/FGFR/RET tyrosine kinase inhibitor for treating cancer
RU2729936C2 (ru) 2015-06-16 2020-08-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противораковое средство
SG11201801083UA (en) 2015-08-20 2018-03-28 Eisai R&D Man Co Ltd Tumor therapeutic agent
JP2018529719A (ja) 2015-09-30 2018-10-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ａｌｋ陰性がんを処置するためのｐｄ−１系結合アンタゴニストおよびａｌｋ阻害剤の組合せ
US12066428B2 (en) * 2015-11-20 2024-08-20 Agilent Technologies, Inc. Cell-substrate impedance monitoring of cancer cells
CN109890387B (zh) 2016-05-20 2022-06-14 拜尔哈文制药股份有限公司 谷氨酸调节剂与免疫疗法用以治疗癌症的用途
GB201616116D0 (en) * 2016-09-22 2016-11-09 Astrazeneca Ab Use of c-Met inhibitors to treat cancers harbouring MET mutations
KR102539920B1 (ko) 2017-02-08 2023-06-05 에자이 알앤드디 매니지먼트 가부시키가이샤 종양-치료용 약제학적 조성물
SG11201910100PA (en) 2017-05-16 2019-11-28 Eisai R&D Man Co Ltd Treatment of hepatocellular carcinoma
CN108047231B (zh) * 2018-01-02 2020-02-11 江苏医药职业学院 [1,2,4]三嗪并[6,1-a]异吲哚化合物的盐酸盐及其应用
IT201800003875A1 (it) * 2018-03-22 2019-09-22 Metis Prec Medicine Sb S R L Nuova combinazione di agenti terapeutici per il trattamento di un tumore e/o metastasi
EP4007585A4 (en) 2019-08-02 2023-11-08 OneHealthCompany, Inc. TREATMENT OF CANINE CANCERS

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4725601A (en) 1985-06-04 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Certain imidazo[1,2-a]pyridines useful in the treatment of ulcers
GB9201693D0 (en) 1992-01-27 1992-03-11 Smithkline Beecham Intercredit Compounds
JPH07109260A (ja) 1993-10-12 1995-04-25 Fuji Photo Film Co Ltd ５−アミノ−２−ニトロピリジン誘導体及び２，５−ジアミノ−３−ヒドロキシピリジン誘導体の製造方法
ES2161290T3 (es) * 1995-03-30 2001-12-01 Pfizer Derivados de quinazolina.
SE9700661D0 (sv) 1997-02-25 1997-02-25 Astra Ab New compounds
SE9801526D0 (sv) 1998-04-29 1998-04-29 Astra Ab New compounds
GB9908410D0 (en) 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
MXPA01010292A (es) * 1999-04-15 2002-10-23 Squibb Bristol Myers Co Inhibidores ciclicos de la proteina tirosina cinasa.
JP2003523942A (ja) 1999-06-30 2003-08-12 メルク エンド カムパニー インコーポレーテッド Ｓｒｃキナーゼ阻害剤化合物
BR0108363A (pt) 2000-02-16 2004-02-10 Neurogen Corp Composto, métodos para modular função de receptor de crf e acoplado a proteìna g, para tratar um distúrbio ou doença do snc, para localizar receptores de crf em amostras de seção de tecidos, para inibir a ligação de crf a um receptor de crf¹ e para alterar a atividade de transdução de sinal de um receptor de crf¹ e composição farmacêutica
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
US6992087B2 (en) 2001-11-21 2006-01-31 Pfizer Inc Substituted aryl 1,4-pyrazine derivatives
MXPA05009063A (es) * 2003-02-26 2005-12-12 Sugen Inc Compuestos de aminoheteroarilo como inhibidores de proteina cinasa.
WO2005026129A1 (en) * 2003-09-15 2005-03-24 Gpc Biotech Ag Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases
AU2004319815A1 (en) * 2004-05-05 2005-12-01 Celgene Corporation Methods and compositions using selective cytokine inhibitory drugs for treatment and management of cancers and other diseases
CN101023064B (zh) 2004-08-26 2011-02-16 辉瑞大药厂 作为蛋白激酶抑制剂的对映异构体纯的氨基杂芳基化合物
ES2355923T3 (es) * 2004-08-26 2011-04-01 Pfizer, Inc. Compuestos de aminoheteroarilo sustituidos con pirazol como inhibidores de proteina quinasa.
WO2006021886A1 (en) 2004-08-26 2006-03-02 Pfizer Inc. Aminoheteroaryl compounds as protein tyrosine kinase inhibitors
EP1963302B1 (en) * 2005-12-05 2013-02-27 Pfizer Products Inc. Polymorphs of a c-met/hgfr inhibitor

Also Published As

Publication number Publication date
RU2384331C2 (ru) 2010-03-20
SI1959955T1 (sl) 2011-02-28
CA2632286C (en) 2011-11-15
NZ568654A (en) 2012-02-24
CY1110931T1 (el) 2015-06-10
US7825137B2 (en) 2010-11-02
CA2632286A1 (en) 2007-06-14
IL191471A (en) 2013-03-24
PL1959955T3 (pl) 2011-04-29
AU2006323027A1 (en) 2007-06-14
US20080300273A1 (en) 2008-12-04
AU2006323027B2 (en) 2012-08-02
TW200727899A (en) 2007-08-01
HK1126121A1 (en) 2009-08-28
ATE488237T1 (de) 2010-12-15
DE602006018354D1 (de) 2010-12-30
BRPI0619424B1 (pt) 2022-02-08
WO2007066187A2 (en) 2007-06-14
RU2008122471A (ru) 2009-12-10
KR20080072965A (ko) 2008-08-07
EP1959955A2 (en) 2008-08-27
WO2007066187A3 (en) 2008-01-17
DK1959955T3 (da) 2011-02-07
JP2007153894A (ja) 2007-06-21
IL191471A0 (en) 2009-08-03
KR101026676B1 (ko) 2011-04-04
BRPI0619424A2 (pt) 2011-10-04
JP4619346B2 (ja) 2011-01-26
PT1959955E (pt) 2011-01-04
EP1959955B1 (en) 2010-11-17
TWI321050B (en) 2010-03-01

Similar Documents

Publication Publication Date Title
AR056832A1 (es) Procedimiento para tratar el crecimiento celular anormal
TW200730522A (en) Polymorphs of a C-MET/HGFR inhibitor
HUS2100051I1 (hu) Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére
CR20110326A (es) Compuestos pirazina como inhibidores de fosfodiesterasa 10
WO2009059304A3 (en) Compounds for treating abnormal cellular proliferation
MX2011001679A (es) Derivados de flavina.
HN2006042221A (es) Derivados de piridina para el tratamiento del crecimiento celular anormal
MA32319B1 (fr) Derives de triazine utiles comme inhibiteurs de la kinase pi3 et de mtor
MY146989A (en) Kinase inhibitors
HN2005000212A (es) Derivados de pirimidina para el tratamiento del crecimiento celular anormal
AR051653A1 (es) Formulaciones
MX2009010034A (es) Pirimidodiazepinas sustituidas utiles inhibidores de la plk1.
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
ECSP17020133A (es) Derivados de benzodiazepina citotóxicos
CL2011001947A1 (es) Compuestos derivados de fenil-{1,2,4}triazolo[1,5-a]piridin-fenilamino sustituidos, inhibidores de cinasa; utiles para tratar trastornos asociados con la permeabilidad vascular.
TW200714283A (en) Method and composition for treating peripheral vascular diseases
PT2470546E (pt) Compostos de hexa-hidrooxazinopteridina para serem utilizados como inibidores de mtor
MX2009007564A (es) Composiciones y metodos para diagnosticar, tratar, y prevenir afecciones de la prostata.
UY32331A (es) Compuestos novedosos como ligandos de receptores de canabinoides
WO2007100777A3 (en) Methods for the treatment of adhd and related disorders
ZA200803420B (en) Formulations comprising jorumycin-, reni eramycin-, safracin-related or saframycin-related compounds for treating proliferative diseases
WO2007024971A3 (en) Hedgehog pathway antagonists to treat disease
GEP20104941B (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods
UA88638C2 (ru) Бета-карболины, полезные для лечения воспалительного заболевания
WO2009103061A3 (en) Methods and compositions for identifying, diagnosing, and treating neuroblastoma

Legal Events

Date Code Title Description
FC Refusal